AstraZeneca plc (ADR)

NYSE: AZN
$53.76
-$0.21 (-0.4%)
Closing price July 10, 2020
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S. District Court ruling that blocked its patents on the medication Vascepa, the company’s chief executive says....
Until late Monday, Amarin continued to get good news relevant to Vascepa, its treatment for cardiovascular disease. The big news, though, was lurking in Nevada federal district court.
Some investors are looking for conservative growth ideas, and big pharma may be the ticket. These four top stocks have been hit hard, and the companies have paid dependable dividends for years.
24/7 Wall St. screened the Merrill Lynch health care research database looking for large pharmaceutical leaders that also pay solid and dependable dividends. These five make sense for growth and...
When companies see their shares rise by 100% or more in a single day, it's usually because of a buyout or an extremely positive change in a company's future prospects. For Genprex, it was a nod from...
AstraZeneca has announced that the FDA has approved its companion diagnostic test that identifies patients with metastatic pancreatic cancer.
The top analyst upgrades, downgrades and initiations for Wednesday included Acorda Therapeutics, Activision Blizzard, Bloom Energy, Care.com, CBS, Deere and Ferrari.
Inovio Pharmaceuticals shares dipped on Wednesday after it was announced that the firm’s partnership with AstraZeneca would be scaled back.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Alcoa, Broadcom, Dow, Lyft, Netflix, Roku, Walt Disney, Wingstop and Xilinx.
The top analyst upgrades, downgrades and initiations seen on Monday included Amazon.com, CarMax, Celgene, Chevron, Exxon Mobil, Lyft, FedEx, Peabody Energy, UPS and Wells Fargo.
Here are five top health care stocks that recently saw their 50-day moving average cross below the 200-day average, a death cross.
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February and March.
The top analyst upgrades, downgrades and initiations seen on Friday included Avaya, AstraZeneca, HD Supply, HubSpot, Intel, Norfolk Southern, Ultimate Software and Valero Energy.
The top analyst upgrades, downgrades and initiations seen on Friday included Activision Blizzard, BioMarin Pharmaceuticals, Ciena, Delta Air Lines, GlaxoSmithKline, Procter & Gamble, Regeneron...